pirenzepine has been researched along with Bulimia in 2 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Bulimia: Eating an excess amount of food in a short period of time, as seen in the disorder of BULIMIA NERVOSA. It is caused by an abnormal craving for food, or insatiable hunger also known as ox hunger.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors explored the binge eating symptomatology in 74 patients receiving clozapine (N = 57) or olanzapine (N = 17), and compared body mass index (BMI, kg/m(2)) and weight gain in patients with and without binge eating symptomatology." | 7.72 | Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. ( Hebebrand, J; König, IR; Linden, A; Martin, M; Remschmidt, H; Theisen, FM, 2003) |
| "In view of the important role played by the cholinergic system in the neural regulation of growth hormone (GH) secretion, the ability of pirenzepine, a selective antagonist of muscarinic cholinergic receptors, to blunt the GH response to GH-releasing hormone (GHRH) was studied in adolescent females with anorexia nervosa in the acute (AN-AP) five AN-AP patients, administration of GHRH 1-40 (1 microgram/kg IV) evoked a significantly higher GH response than in controls at established intervals, whereas in eight AN-RP and seven AED patients it was higher than in controls at only one (150-min) and two (150-min, 180-min) time intervals, respectively." | 7.68 | Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders. ( Andreoni, A; Belliti, D; Cristofani, R; Ferdeghini, M; Müller, EE; Rolla, M, 1991) |
| "The authors explored the binge eating symptomatology in 74 patients receiving clozapine (N = 57) or olanzapine (N = 17), and compared body mass index (BMI, kg/m(2)) and weight gain in patients with and without binge eating symptomatology." | 3.72 | Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. ( Hebebrand, J; König, IR; Linden, A; Martin, M; Remschmidt, H; Theisen, FM, 2003) |
| "In view of the important role played by the cholinergic system in the neural regulation of growth hormone (GH) secretion, the ability of pirenzepine, a selective antagonist of muscarinic cholinergic receptors, to blunt the GH response to GH-releasing hormone (GHRH) was studied in adolescent females with anorexia nervosa in the acute (AN-AP) five AN-AP patients, administration of GHRH 1-40 (1 microgram/kg IV) evoked a significantly higher GH response than in controls at established intervals, whereas in eight AN-RP and seven AED patients it was higher than in controls at only one (150-min) and two (150-min, 180-min) time intervals, respectively." | 3.68 | Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders. ( Andreoni, A; Belliti, D; Cristofani, R; Ferdeghini, M; Müller, EE; Rolla, M, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Theisen, FM | 1 |
| Linden, A | 1 |
| König, IR | 1 |
| Martin, M | 1 |
| Remschmidt, H | 1 |
| Hebebrand, J | 1 |
| Rolla, M | 1 |
| Andreoni, A | 1 |
| Belliti, D | 1 |
| Cristofani, R | 1 |
| Ferdeghini, M | 1 |
| Müller, EE | 1 |
2 other studies available for pirenzepine and Bulimia
| Article | Year |
|---|---|
Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Bulimia; Clozapine; Femal | 2003 |
Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders.
Topics: Adolescent; Anorexia Nervosa; Body Weight; Brain; Bulimia; Estradiol; Female; Follicle Stimulating H | 1991 |